title: [My patient is too old for a lipid-lowering therapy: myths and reality].
abstract: Lipid-lowering treatment in the elderly patient is conditioned by a high incidence and prevalence of cardiovascular disease in the setting of a limited remaining life span. The clinical benefit of statin therapy can be seen after a few months, thus supporting use in secondary prevention even when the lifespan is restricted to a few years. Recent guidelines propose the use of moderate doses in the elderly > 75 years. The evidence for treatment in primary prevention is weaker and the evaluation of the total cardiovascular risk is complicated by the high baseline risk of many elderly. Rational treatment decisions should be based on biologic rather than chronologic age. Statins are generally well tolerated in the elderly, requiring clinical monitoring only, with particular attention to pharmacokinetic interactions and renal failure.
authors.forename: V
authors.initials: V
authors.lastname: Steenpass
authors.forename: A Tahar
authors.initials: AT
authors.lastname: Chaouche
authors.forename: F
authors.initials: F
authors.lastname: Mach
authors.forename: J-L
authors.initials: JL
authors.lastname: Reny
authors.forename: G
authors.initials: G
authors.lastname: Ehret
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000075202:Contraindications; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents